, Ronald L. Ariagno, MD 13 , Laura Fabbri, PhD 11 , and Mark A. Turner, MD 14 , for the International Neonatal Consortium C hronic pulmonary insufficiency is the most common health morbidity of extremely preterm birth. It is associated with increased resource utilization during the initial hospitalization, as well as short-term and longer-term respiratory morbidities that drive health care costs and are associated with worse neurodevelopmental outcomes. 1 Chronic pulmonary insufficiency of prematurity (CPIP) refers to respiratory morbidity after preterm birth during the birth hospitalization and through infancy and childhood (Figure) . It is usually captured during the initial hospitalization with a diagnosis of bronchopulmonary dysplasia (BPD). Despite advances in respiratory management, the incidence of BPD in the smallest neonates continues to rise, 2 and there have been few therapeutic advances over the last 25 years. 3 The many reasons for these ongoing gaps in drug development include difficulties with clinical trial design, a population viewed as high risk by regulators and industry, and the need to wait months or even years to establish safety and efficacy. These problems are compounded by definitions of BPD that are applied inconsistently and are not clearly related to long-term outcomes of importance to clinicians and families.
Consideration of a broader concept of CPIP is important because the diagnosis of BPD does not capture all infants with chronic pulmonary insufficiency. The concept of BPD grew out of radiologic and pathological examinations of neonates with significant lung injury, and assumes that an oxygen requirement stems from lung damage that is similar between infants, and that different lung insults produce similar effects on the lung. Although oxygen dependence is related to injury of the lung parenchyma, it also may be influenced by injury to or immaturity of the brain, airways, or pulmonary vasculature. Moreover, an early measure of gas exchange might not reflect the pathophysiology of later problems, such as reactive airway disease or susceptibility to viral infections. Optimizing and harmonizing clinical definitions of CPIP, including BPD and later respiratory outcomes, while developing strong surrogate endpoints useful for regulators, industry, clinicians, and families would greatly benefit future interventional trials and accelerate the development of new therapies for these highrisk and vulnerable patients.
Current Endpoints: Benefits and Limitations for Drug Development
The definition of BPD has evolved considerably over the past 50 years, in conjunction with improved survival for extremely low birth weight (ELBW) infants (Table I) . Although CPIP exists on a continuum of disease severity over time, BPD is defined as a dichotomous (yes/no) outcome of the requirement for supplemental O2 at an arbitrary 36-weeks postmenstrual age (PMA) time point. There is not a consensus that BPD is predictive of chronic pulmonary insufficiency or represents the most appropriate definition for clinical trials of drug development. 4 A systematic review found that many clinical trials did not use a discrete definition of BPD, 5 a situation complicated by the absence of biomarkers or imaging techniques to characterize or predict BPD.
An additional challenge is that the criteria for O2 use in treating upper airway disease or immaturity of respiratory control (eg, apnea, feeding difficulties) vary among centers and among clinicians. For example, in the multicenter Prematurity and Respiratory Outcomes Program (PROP) study, 47% of 765 surviving ELBW infants remained on nasal cannula support at 36 weeks PMA, but with substantial variation in the flow and/or O2 concentrations used. 6 Although an infant receiving 21% O2 delivered at 4 L/minute by high-flow nasal cannula would be classified as "no BPD" by the Shennan definition, whether this infant will have less intrinsic lung disease and better longterm outcomes compared with an infant receiving 0.1 L/minute of 100% O2 and classified as "severe BPD" it is not known.
BPD is a functional description that is not correlated with specific mechanisms but has become shorthand for CPIP in general. A functional description may be useful in clinical trials as a way to capture multiple influences; however, the current 36-week PMA definition of BPD remains an imperfect surrogate to predict chronic pulmonary morbidity in infancy, later childhood, and adolescence. For instance, some interventions, such as vitamin A, significantly reduced the incidence of BPD at 36 weeks PMA, but had no affect on long-term respiratory morbidity. 7, 8 Other interventions, such as highfrequency oscillatory ventilation, superoxide dismutase, and late surfactant, failed to reduce BPD but did improve longerterm respiratory outcomes. [9] [10] [11] These discrepancies may reflect the range of tissues that can be injured in preterm infants. Vitamin A may support more efficient gas exchange in the short term but have no effect on airways, whereas other interventions may have dominant effects on airways or other tissues. BPD still may be a useful as a functional clinical outcome that captures lung function at the time when a preterm infant should transition out of the hospital, in the way that functional outcomes, such as forced expiratory volume in 1 second, are useful in such conditions as cystic fibrosis.
Goals of Definitions: Perspectives of Clinicians, Industry, Regulators, and Parents
How should respiratory disease of prematurity be optimally defined for the purposes of drug development? Ideally, a definition would be clinically meaningful and strongly associated with the subsequent development of long-term respiratory morbidities. The definition should be objective and standardized, and incorporate unambiguous, specific guidance about how to factor in the use of O2 and noninvasive respiratory support. Considering that other morbidities of prematurity (eg, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage) are measured on a scale, a validated "BPD severity scale" ranging from no morbidity (no O2, respiratory support, or medications) to severe morbidity would be useful. Because these infants are often not appropriately classified, definitions should use components that are easily extractable from the health record, and allow for the reliable evaluation of infants transferred to another hospital or discharged before the optimal time for BPD assessment,. 6, 12 Definitions also should incorporate infants who die of progressive lung injury between 7 days of life and 36 weeks PMA, because these infants may gain the most from early/prophylactic treatment approaches.
From the perspective of the pharmaceutical industry, a simple and pragmatic definition will encourage its introduction into routine neonatal clinical practice in all hospitals, not only at university-and research-based institutions. Regulatory authorities need to assess whether endpoints other than survival measure a meaningful aspect of how a patient feels or functions in daily life. Endpoints should display good interobserver and intraobserver agreement and stability over time in individual infants, and have a predictable relationship to mechanisms that are amenable to drug therapy, which will facilitate dose selection and the development of biomarkers.
Industry, trialists, and regulators also need to consider the perspective of parents on what constitutes meaningful outcomes. Composite outcomes, such as "death or BPD," can be difficult for parents to understand, not viewing these competing outcomes as equivalent. 13 Moreover, if an infant survives, the requirement for a nasal cannula at 36 weeks PMA has a very different impact compared to the need for home oxygen or ventilation. Moving beyond the dichotomous BPD outcome to include the long-term consequences of lung injury will measure outcomes that are important in this group.
Proposed Endpoints for Clinical Trials That Investigate CPIP
36 Weeks PMA Compared with term infants, ELBW infants are at greater risk for pulmonary morbidity. Preterm infants with BPD have longer initial hospitalizations and increased rates of death and longterm disability, use of respiratory medications, and abnormal pulmonary function during childhood.
14 However, other studies have failed to demonstrate significant differences in longterm pulmonary outcomes for infants with and without BPD at 36 weeks PMA, [14] [15] [16] leading regulators to increasingly view the 36-week endpoint as inadequate for drug approval.
Restricting the diagnosis of BPD to a dichotomous outcome limits information about the disease itself. The definition of BPD at 36 weeks PMA should be expanded to a continuous outcome that incorporates all methods of noninvasive respiratory support and use of respiratory medications (eg, diuretics, bronchodilators, corticosteroids) that can influence the need for supplemental O2. We propose incorporating a simple respiratory checklist administered at 36 weeks PMA or discharge into the health records of all preterm infants, to allow for the development of an objective BPD scoring system, particularly for those infants transferred to another hospital or discharged to home (Table II) . Endpoints at 36 weeks PMA also should incorporate pulmonary hypertension (PH) screening for infants with moderate to severe BPD, which is found in 10%-15% of this population and is associated with higher mortality and morbidity. [17] [18] [19] Finally, the 36-week PMA determination is typically made on a single day during the 36th postmenstrual week, despite changing needs for supplemental O2 due to the immaturity in control of breathing, feeding patterns, and airway protection inherent to this time period. This variability in timing likely contributes to the poor longterm predictive value of a 36-week PMA diagnosis. We recommend extending the assessment of oxygen dependency to maintain oxygen saturation in the normal range (90%-95%), and to include at least 3 consecutive days of the 36th postmenstrual week.
40 Weeks PMA Because immature respiratory control and feeding difficulties often resolve by term equivalent, targeting a 40-week PMA endpoint may avoid the pitfalls of the 36-week endpoint and better identify those infants with persistent airway and/or parenchymal disease. Although some infants will already be discharged, the PROP cohort found that 41% of survivors (315 of 765) were still hospitalized at 40 weeks PMA. 6 A child could be imputed as "no BPD" at 40 weeks PMA or the time of discharge if off all respiratory support (including noninvasive methods) for a predetermined period (eg, 7 days). The result would be an alternative definition at 40 weeks PMA or discharge that is dichotomous ("no BPD" if in room air with no support,"yes BPD" if receiving any form of support) but also continuous by assigning a score based on level of respiratory support. A numeric scale that incorporates inspired O2 concentration, O2 flow rate, and medication use would be a statistically more powerful outcome than a simple dichotomous outcome. For instance, data from the Canadian Neonatal Network show that a combined outcome of O2 and December 2017 20 This time point remains to be validated in multiple international cohorts, however.
MEDICAL PROGRESS
1 Year CGA Premature infants more frequently have pulmonary morbidity at school age and beyond, including asthma, repeated pulmonary infections, exercise intolerance, and lung function abnormalities. 14, 16 These are important outcomes, but impractical endpoints for most neonatal interventional trials. In addition, these long-term respiratory morbidities may occur regardless of the development of BPD, suggesting that mechanisms for longer-term pulmonary morbidity may differ from those causing O2 dependency at 36 weeks PMA. 21 One small study suggested that pulmonary function testing at 1 year CGA predicted respiratory symptoms at age 5 years even though a diagnosis of BPD at 36 weeks did not. 22 Unfortunately, lung function assessments at 1 year CGA use complex equipment not available at most centers and involve sedation of the infant, leading most parents to refuse consent. 23 Such outcomes as the need for rehospitalization, home O2 therapy, and frequent visits to a health care provider or the emergency department in the first years of life have not been systematically reported in most studies, although this is beginning to change. 24, 25 The use of respiratory medications (eg, bronchodilators, inhaled/systemic steroids, leukotriene inhibitors) to treat respiratory symptoms or illnesses during the first year of life also suggests the presence of chronic respiratory morbidity, but is limited by the absence of evidence of efficacy, clear standards for treatment, and marked intercenter variability.
In one study, a 4-week respiratory diary card completed by parents at 1 year CGA captured the extent of coughing, wheezing, and respiratory medication use and was highly predictive of 2-year respiratory outcomes. 15 That study did not identify rehospitalization as a significant predictor of longer-term respiratory dysfunction; however, the total number and duration of hospital readmissions were related to the severity of BPD and are clinically meaningful outcomes for families. The biggest problem with using a primary 1-year outcome measure is the impact of confounding variables, including environmental factors such as smoking in the home, medication compliance (including any immunoprophylaxis), and respiratory syncytial virus and other viral infections. Furthermore, although rates of follow-up are 97% in the United Kingdom and Australia, improved rates of follow-up in other countries, including the US, would need to be achieved.
Other Outcome Considerations
Preterm infants with continuing pulmonary insufficiency at the time of hospital discharge present a significant challenge for parents, other family members, and primary care providers. Common problems for these infants include marginal nipple feeding; the need for partial or complete gavage feeding; fussiness, irritability, and inconsolability; and the need for multiple medications and medical visits. Such outcomes as growth, sleep patterns, behavioral and neurodevelopmental issues, and parental stress are also very important. 13 An objective quality of life scale is needed for this age group to obtain input from the parent as well as timely observations regarding the infant. The PedsQL Pediatric Quality of Life Inventory Infant Scales is one such instrument for children aged 2-12 years (www.pedsql.org/index.html). There is a need for smart mobile tools to provide an easily accessible portal for parents to complete serial quality of life assessments.
Identification of Severe or Early Lethal CPIP
The population of ELBW infants most in need of innovative therapies may be those who die of "early, lethal BPD" before a diagnosis of BPD can be formally made. The cause of death is often imprecisely assigned for these infants. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network examinination of deaths over a 19-year period found that infants died of "respiratory distress syndrome" well past the first week of life, and died of "BPD" before 36 weeks PMA. 26 In the recent PROP cohort, 63 of 835 ELBW infants died before 36 weeks PMA. 6 Of the 35 infants who died after 2 weeks of age, 25 (71%) were retrospectively adjudicated to have had chronic respiratory failure as a primary cause of death. Chronicity was arbitrarily assessed by the respiratory status within 7 days of death, with many of these infants having been assigned other causes of death. Thus, approximately 3% of the entire cohort had "early lethal BPD."
Clinical trials often report the combined outcome of death or BPD because death before 36 weeks PMA is a competing adverse outcome. However, neither epidemiologic reports nor trial reports independently identify deaths due to severe respiratory failure before 36 weeks PMA. These deaths are often associated with elements of a BPD phenotype, and some of these deaths may be due to complications (eg, sepsis) that may have occurred secondary to the care needed to support the respiratory failure, such as the prolonged need for vascular access and respiratory support, nutritional deficits, and prolonged antibiotic exposure.
The concept of severe CPIP or BPD also should evolve to better capture those infants who survive to 36 or 40 weeks PMA and experience severe respiratory failure necessitating aggressive treatment. There is a need for valid predictors for the severe form of CPIP that can be applied soon after birth and within the first several weeks of life, because these infants should be specifically targeted for trials of innovative therapies. A modified NICHD BPD calculator may be a good option for such a predictive instrument. 27 For example, the continued need for mechanical ventilation at day 7 is a strong indicator for increased BPD risk, yet likely indicates the need for even earlier predictors (eg, antenatal factors, need for resuscitation).
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Perinatal Risk Factors: Implications for Preventive Studies
Many of the factors and comorbidities associated with CPIP can be used to identify populations at highest risk. Such antenatal factors as intrauterine growth restriction (IUGR), maternal hypertension, maternal smoking, and male sex are now appreciated as key risk factors and highly predictive of chronic respiratory morbidity. 24, 28 Postnatal events that increase the risk of BPD include severe respiratory failure, air leak, early PH, systemic and pulmonary infections, and the prolonged presence of a patent ductus arteriosus.
Intrauterine Growth Restriction
One of the strongest factors reflecting the impact of fetal events in the pathogenesis of BPD is the presence of IUGR. 29, 30 In one large study of preterm infants born at ≤28 weeks gestation, birth weight z-scores indicative of IUGR were more strongly linked with increased risk for BPD than numerous other prenatal, placental, and postnatal factors. 29 Furthermore, IUGR is an independent risk factor for late respiratory morbidities and abnormal lung function (eg, abnormal airway function, decreased lung surface area) at school age.
31,32
Placental Abnormalities Hypertensive disorders of pregnancy, such as preeclampsia, have been strongly associated with the development of BPD after preterm birth, even after accounting for IUGR. 33 Experimental models that alter placental function and structure to create severe IUGR impair fetal lung airspace and vascular growth in the late gestation fetus, which may persist throughout postnatal life. 34 In preterm infants with IUGR, histological placental abnormalities of "maternal underperfusion" are strongly linked with BPD and BPD-associated PH. Cord blood biomarkers for assessing BPD risk may include circulating fetal proteins, such as vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor 1).
35
Maternal Smoking
Maternal smoking is a known risk factor for impaired lung function, wheezing, and asthma in children aged 4-12 years 28, 36 and likely contributes to CPIP outcomes. 24, 37 Possible mechanisms underlying the harmful effects of maternal smoking on fetal lung development include dysregulated cytokine production and oxidative stress, as well as direct effects of nicotine on lung receptors resulting in altered lung development and impaired lung function at birth. 38 More recent research has suggested an interaction of in utero and early-life smoke exposure with up-regulation of asthma susceptibility genes, 39 and new evidence suggests that the effects of maternal smoking can be modified by such agents as vitamin C.
40
Inflammation and Infection
Preterm birth is frequently associated with fetal exposure to inflammation/infection as diagnosed by histopathology (eg, chorioamnionitis, funisitis), culture, or increased concentrations of proinflammatory cytokines in amniotic fluid or cord blood. 41 Chorioamnionitis rarely results in invasive infection, but indicators of lung inflammation are frequently found before birth. 42 These antenatal exposures are associated with lung abnormalities ranging from severe diffuse pneumonia (indistinguishable from severe respiratory distress syndrome) to mature lungs for gestational age with lower risk for BPD. Although fetal modulations of immune and inflammatory responses can contribute to postnatal lung injury and the development of BPD, the exact mechanisms are poorly understood. 43 Postnatally, lung inflammation can be triggered by exposure to systemic infection, high O2 concentrations, positive-pressure ventilation, and/or a patent ductus arteriosus. Increased concentrations of inflammatory mediators could contribute to bronchoconstriction, vasoconstriction, and increased vascular permeability characteristic of the lungs of these infants, and might also be responsible for the decreased alveolarization seen in infants dying with BPD. 44 
Pulmonary Vascular Disease
Disruption of pulmonary angiogenesis due to such antenatal factors as chorioamnionitis, preeclampsia, maternal smoking, and postnatal injury can cause pulmonary vascular disease that leads to PH and impaired distal lung growth. 19 Echocardiographic findings of pulmonary vascular disease shortly after preterm birth are strongly associated with the development and severity of BPD and PH at 36 weeks PMA, as well as with late respiratory complications, including respiratory exacerbations, hospitalizations, and the need for asthma medication. 45 Echocardiographic evidence of early PH may be an excellent predictor of severe BPD and an early predictive biomarker for enrolling the highest-risk infants into clinical intervention trials.
Early Respiratory Failure
Severe respiratory distress syndrome and the need for high inspired O2 concentrations and prolonged ventilatory support are clearly associated with an increased incidence of BPD. The ongoing need for respiratory support at day 7 improves the predictive accuracy for BPD, with rates approaching 65%. 27, 46, 47 O2 targeting trials have shown increased pulmonary morbidity in infants maintained within higher O2 target ranges, suggesting that higher inspired O2 may produce worse pulmonary outcomes. A recent secondary analysis of the Trial of Late Surfactant (TOLSURF) data showed a strong association between cumulative O2 exposure during the first 14 days and a higher incidence of BPD at 36 weeks PMA. 48 Thus, an analysis of cumulative inspired O2 concentrations (area under the curve) may permit the early prediction of BPD or other forms of CPIP with a high degree of specificity and sensitivity. 48 
Research Agenda
The research agenda for drug development needs to sharpen its focus on rigorous data collection combined with a mechanistic approach appropriate for clinical scientists.
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MEDICAL PROGRESS
Identification of Subgroups of CPIP Rigorous studies are needed to determine that specific risk subgroups exist and can be reliably identified. Hypotheses about subgroups can be generated from epidemiologic data (including cohorts characterized with modern methods, such as -omics) or from mechanistic data (usually derived from in vitro or animal models). One set of hypotheses could be based on the risk factors described earlier; for example, IUGR could be associated with different pathways and manifestations of CPIP compared with perinatal inflammation. These studies should pay attention to genetic factors that may contribute to severe CPIP. Subgroups could be defined according to a priori criteria or could be identified from linking clinically important outcomes to phenotypic or -omic profiles. Proposed subgroups need to be confirmed using validation cohorts. Biomarker inquiries should cover the preanalytic and analytic characterization of proposed biomarkers and quantification of the variability of those biomarkers observed in the target population.
Identification of Respiratory Outcomes
Specific respiratory outcomes at the proposed time points need to be reliably ascertained as clinically relevant or strongly associated with functionally relevant outcomes. International datasets and registries should be used to determine covariates that contribute to the progression or resolution of chronic pulmonary insufficiency. New techniques should be developed and studied to better standardize pulmonary assessment, such as imaging techniques that measure alveolar number and size 49 or noninvasive measurements of exhaled gases.
Relationships Between Subgroups and Outcomes
Studies are needed to determine whether specific subgroups are strongly associated with clinically significant outcomes. Newer methodologies, such as a phenotype-wide association study, structural equation modeling, and latent variable analysis, should be considered. Characterization needs to include quantification of the variation in the strength of the associations within and across clinical settings, as well as an estimate of the magnitude of the associations.
Impact of a Drug or Other Intervention on an Outcome in Specific Subgroups
This involves testing whether members of a subgroup are more likely to have a beneficial outcome, or less likely to have an adverse outcome, in response to a drug across its therapeutic range.
We suggest that these investigations will require a staged program linking subgroup characterization to outcomes and drug response. The stages could be conducted in parallel in carefully designed studies. The use of BPD as an outcome for drug development in the absence of these steps may be a historic necessity, but it has led to a lack of clarity and may have led to inappropriate rejection of promising drugs. Future work will benefit from the steps that we outline here.
Conclusion
A single definition of CPIP is unlikely to address all the needs of trialists, drug developers, parents, and regulators for meaningful and valid endpoints. For some purposes, refining the existing 36-week PMA definition of BPD to better predict longterm pulmonary insufficiency would retain the advantages of assigning a diagnosis before discharge. There is also a need to better understand the impact of severe lung disease that leads to early mortality before the designation of BPD at 36 weeks; this has been an overlooked population that needs study and warrants clinical trial work. A 40-week PMA definition would be anticipated to reduce the "noise" in the data by eliminating infants with minimal disease, but its predictive value requires further validation. A 1-year CGA outcome capturing features of chronic respiratory morbidity remains essential to regulators and families as a clinically meaningful outcome, but validation, comprehensive follow-up, and the ability to control for postdischarge environmental factors are needed. Finally, identification of subpopulations of infants at highest risk, or with pathophysiology that may benefit from a particular therapy, is needed to allow clinical trials to function optimally and conclude with clear answers. ■
